San Francisco AIDS Foundation
Approved Antiretroviral Drugs
Winter 2005/2006
| Generic (Common) Name | Brand Name | Company | Year Approved |
| Protease Inhibitors (PIs) |
| amprenavir | Agenerase | GlaxoSmithKline | 1999; discontinued 2004
|
| atazanavir | Reyataz | Bristol-Myers Squibb | 2003
|
| fosamprenavir | Lexiva (U.S.); Telzir (Europe) | GlaxoSmithKline | 2003
|
| indinavir | Crixivan | Merck | 1996
|
| lopinavir/ritonavir | Kaletra | Abbott | 2000; Meltrex formulation 2005
|
| nelfinavir | Viracept | Pfizer | 1997
|
| ritonavir | Norvir | Abbott | 1996
|
| saquinavir | Invirase (hard-gel)
Fortovase (soft-gel) | Roche | 1995
1997; withdrawn 2005
|
| tipranavir | Aptivus | Boehringer Ingelheim | 2005
|
| Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) |
| abacavir | Ziagen | GlaxoSmithKline | 1998
|
| didanosine (ddI) | Videx | Bristol-Myers Squibb | 1989; extended release Videx EC 2000
|
| emtricitabine (FTC) | Emtriva | Gilead | 2003
|
| lamivudine (3TC) | Epivir | GlaxoSmithKline | 1995
|
| stavudine (d4T) | Zerit | Bristol-Myers Squibb | 1994
|
| zalcitabine (ddC) | Hivid | Roche | 1992; withdrawn 2005
|
| zidovudine (AZT) | Retrovir | GlaxoSmithKline | 1987
|
| tenofovir DF | Viread | Gilead | 2002
|
| NRTI Fixed-Dose Combinations |
| zidovudine/lamivudine | Combivir | GlaxoSmithKline | 1997
|
| zidovudine/lamivudine/abacavir | Trizivir | GlaxoSmithKline | 2000
|
| lamivudine/abacavir | Epzicom (U.S.); Kivexa (Europe) | GlaxoSmithKline | 2004
|
| tenofovir/emtricitabine | Truvada | Gilead | 2004
|
| Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) |
| delavirdine | Rescriptor | Pfizer | 1997
|
| efavirenz | Sustiva (U.S.); Stocrin (elsewhere) | Bristol-Myers Squibb | 1998
|
| nevirapine | Viramune | Boehringer Ingelheim | 1996
|
| Entry/Fusion Inhibitors |
| enfuvirtide (T-20) | Fuzeon | Trimeris | 2003
|
 |
|
|
This article was provided by
San Francisco AIDS Foundation.
It is a part of the publication Bulletin of Experimental Treatments for AIDS.
